ORCID iD
Qi. Mahttps://orcid.org/0000-0002-5593-1983 .
Li’an.Huanghttps://orcid.org/0000-0002-0416-7532.
References
1.Norhammar A, Mellbin L and Cosentino F. Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor.Eur J Prev Cardiol 2017; 24: 52-60. DOI: 10.1177/2047487317709554.
2.Chandrasekhar J, Dangas G, Baber U, et al. Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. Catheter Cardiovasc Interv 2020 2020/03/13. DOI: 10.1002/ccd.28841.
3.Bawamia BR, Egred M, Jackson M, et al. Percutaneous coronary intervention for left main stem disease: Impact of diabetes mellitus on mortality. Catheter Cardiovasc Interv 2020 2020/03/07. DOI: 10.1002/ccd.28818.
4.Shen L, Rorth R, Cosmi D, et al. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail 2019; 21: 974-984. 2019/07/05. DOI: 10.1002/ejhf.1535.
5.Pepe M, Sardella G, Stefanini GG, et al. Impact of Insulin-Treated and Noninsulin-Treated Diabetes Mellitus in All-Comer Patients Undergoing Percutaneous Coronary Interventions With Polymer-Free Biolimus-Eluting Stent (from the RUDI-FREE Registry). Am J Cardiol 2019; 124: 1518-1527. 2019/09/25. DOI: 10.1016/j.amjcard.2019.08.015.
6.Pi SH, Rhee TM, Lee JM, et al. Outcomes in Patients with Diabetes Mellitus According to Insulin Treatment After Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era. Am J Cardiol 2018; 121: 1505-1511. 2018/05/13. DOI: 10.1016/j.amjcard.2018.02.034.
7.Jil M, Rajnikant M, Richard D, et al. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study. Diab Vasc Dis Res 2017; 14: 295-303. 2017/03/24. DOI: 10.1177/1479164116687102.
8.Herman ME, O’Keefe JH, Bell DSH, et al. Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Prog Cardiovasc Dis 2017; 60: 422-434. 2017/09/30. DOI: 10.1016/j.pcad.2017.09.001.
9.Anfossi G, Massucco P, Mattiello L, et al. Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations. Thromb Res 1996; 82: 57-68. 1996/04/01. DOI: 10.1016/0049-3848(96)00051-5.
10.Chakraborty K and Sinha AK. The role of insulin as an antithrombotic humoral factor. Bioessays 2004; 26: 91-98. 2003/12/30. DOI: 10.1002/bies.10375.
11.Vivas D, Garcia-Rubira JC, Bernardo E, et al. Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study (”Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo”).Heart 2011; 97: 803-809. 2011/03/08. DOI: 10.1136/hrt.2010.219949.
12.Vivas D, Garcia-Rubira JC, Bernardo E, et al. Effect of an optimized treatment with insulin on platelet reactivity after discharge in patients with an acute coronary syndrome and hyperglycemia. Rev Esp Cardiol (Engl Ed) 2014; 67: 22-27. 2014/04/30. DOI: 10.1016/j.rec.2013.05.020.
13.Westerbacka J, Yki-Jarvinen H, Turpeinen A, et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol2002; 22: 167-172. 2002/01/15. DOI: 10.1161/hq0102.101546.
14.Ma Q, Chen GZ, Zhang YH, et al. Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events. Chin Med J (Engl) 2019; 132: 1053-1062. 2019/03/22. DOI: 10.1097/CM9.0000000000000210.
15.Tantry US and Gurbel PA. Assessment of oral antithrombotic therapy by platelet function testing. Nat Rev Cardiol 2011; 8: 572-579. DOI: 10.1038/nrcardio.2011.107.
16.Tang XF, Han YL, Zhang JH, et al. Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel. Chin Med J (Engl) 2015; 128: 774-779. DOI: 10.4103/0366-6999.152611.
17.Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events.Am Heart J 2010; 160: 346-354. DOI: 10.1016/j.ahj.2010.05.034.
18.Shen W, Zhou JY, Gu Y, et al. Establishing a reference range for thromboelastography maximum amplitude in patients administrating with antiplatelet drugs. J Clin Lab Anal 2019: e23144. 2019/12/08. DOI: 10.1002/jcla.23144.
19.Hobson AR, Petley GW, Dawkins KD, et al. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography.Platelets 2007; 18: 497-505. DOI: 10.1080/09537100701329162.
20.Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol2006; 48: 298-304. DOI: 10.1016/j.jacc.2006.03.038.
21.Alexopoulos D, Vogiatzi C, Stavrou K, et al. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study. Cardiovasc Diabetol 2015; 14: 68. 2015/05/31. DOI: 10.1186/s12933-015-0232-1.
22.Yki-Jarvinen H. Nonglycemic effects of insulin. Clin Cornerstone 2003; Suppl 4: S6-12. 2004/02/28. DOI: 10.1016/s1098-3597(03)90061-5.
23.Spectre G, Ostenson CG, Li N, et al. Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes. Diabetes 2012; 61: 2380-2384. 2012/06/13. DOI: 10.2337/db11-1806.
24.Spectre G, Stalesen R, Ostenson CG, et al. Meal-induced platelet activation in diabetes mellitus type 1 or type 2 is related to postprandial insulin rather than glucose levels. Thromb Res 2016; 141: 93-97. 2016/03/20. DOI: 10.1016/j.thromres.2016.03.009.
25.Trovati M and Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002; 16: 35-40. 2002/03/02.
26.Suslova TE, Sitozhevskii AV, Ogurkova ON, et al. Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation. Front Physiol 2014; 5: 501. 2015/01/21. DOI: 10.3389/fphys.2014.00501.
27.Ferreira IA, Eybrechts KL, Mocking AI, et al. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004; 279: 3254-3264. 2003/11/07. DOI: 10.1074/jbc.M305474200.
28.Udvardy M, Pfliegler G and Rak K. Platelet insulin receptor determination in non-insulin dependent diabetes mellitus.Experientia 1985; 41: 422-423. 1985/03/15. DOI: 10.1007/bf02004539.
29.Boden G and Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep2007; 7: 223-227. 2007/06/06.
30.Gerrits AJ, Koekman CA, van Haeften TW, et al. Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes 2010; 59: 1487-1495. DOI: 10.2337/db09-1008.
31.Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26: 417-422. DOI: 10.1161/01.ATV.0000199519.37089.a0.